- In March 2024, Roche Diagnostics launched a new liquid biopsy test for early detection of lung cancer. This non-invasive test is designed to detect circulating tumor DNA (ctDNA) in blood samples, providing a more convenient and less invasive alternative to traditional tissue biopsies.
- In February 2024, Thermo Fisher Scientific introduced a new next-generation sequencing (NGS) platform for comprehensive genomic profiling of cancer. This platform enables researchers and clinicians to identify a wide range of genetic mutations associated with cancer, facilitating personalized treatment strategies.
- In January 2024, Abbott Laboratories received FDA approval for a new immunohistochemistry (IHC) assay for the diagnosis of breast cancer. This assay helps in the identification of specific biomarkers that can guide treatment decisions and predict patient outcomes.
- In December 2023, Siemens Healthineers launched a new molecular diagnostics system for the detection of infectious diseases associated with cancer. This system enables rapid and accurate identification of pathogens, helping to improve the management of cancer patients with infections.
- In November 2023, Danaher Corporation announced a collaboration with a leading research institute to develop new artificial intelligence (AI)-based tools for cancer diagnosis. This collaboration aims to improve the accuracy and efficiency of cancer detection and diagnosis using advanced AI algorithms.
